Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07160751
Recruiting Observational

Cognition and Patients With Lung Cancer

NCT07160751 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Started
2026-04-24
Last updated
2026-10-22

Condition(s) studied

Localized, Operable Non-small Cell Lung Cancer

Investigational drug(s) / intervention(s)

Self-questionnaireCognitive testsAssessment of the impact of social vulnerability on patient complaints

Self-questionnaire: FACT-Cog, HADS, FA12, EPICES, socio-professional and socio-demographic questionnaire

Cognitive tests: Hopkins Verbal Learning Test (HVLT). Trail Making Test (TMT). Verbal fluency test. Digit memory WAIS-IV.

Assessment of the impact of social vulnerability on patient complaints: EPICES at month 12

Study summary

Cognitive complaints in patients treated for cancer can impact their quality of life.

Studies show that these cognitive complaints may have multifactorial origins and appear at different stages of the care pathway.

In a population of patients treated for confirmed localized non-small cell lung cancer (NSCLC), this study aims to detect and monitor the onset of cognitive complaints over time.

The timing of the complaints during the treatment, the cognitive functions affected (memory, attention, concentration…), as well as the perceived intensity of the discomfort, will be examined.

The study also explores the influence of co-factors such as mood, fatigue, socio-cultural status, and level of social vulnerability on these cognitive complaints.

Eligibility

Sex
ALL
Min age
18 Years
Max age
74 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Adult patient aged 18 to 74 years * Suspected or confirmed localized and operable non-small cell lung cancer (NSCLC) * Surgical treatment with or without perioperative systemic medical therapy * Ability to independently complete self-questionnaires via the Cleanweb platform * Patients with access to a phone, tablet, or computer at home to complete the electronic self-questionnaires. Exclusion Criteria: * Known pre-existing cognitive disorders * Presence on the day of inclusion of one or more factors causing mental confusion: electrolyte imbalances, renal failure, hepatic failure, infections, bladder distension, fecal impaction * Known psychiatric or neurological diseases (e.g., multiple sclerosis, Parkinson's disease, dementia, stroke, traumatic brain injury with loss of consciousness) * Current use of neuroleptic treatments * History of cancer treatment within the past 10 years * Fibromyalgia * Individuals who cannot read French or are not French-speaking * Patients who have never attended school

Primary outcome measure(s)

  • To examine the onset, intensity and duration of the PCI (Perceived Cognitive Impairment) score — 12 months
    Functional Assessment of Cancer Therapy - Cognitive Function (FACT-Cog) self-report questionnaire : min =0, max=132

Trial sites (1)

FacilityCityRegionStatus
Hôpital Cochin - Service de pneumologie Paris Île-de-France Region Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases Recruiting
VExUS in Ards Patients and Association with AKI Recruiting
Periodontitis and Inflammation: Study on Biological Samples Recruiting
Kinematic Analysis of Latissimus Dorsi Transfer Results for Shoulder External Rotation Resuscitation Starting soon
Creation of a Biological Collection for Medical Research Purposes for Patients at the Reference Center for Rare Diseases of the Blood Vessels of the Brain and Eye at Lariboisière Hospital Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07160751 on ClinicalTrials.gov ↗ ← All trials in France